ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$17.98 USD
+0.18 (1.01%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $17.97 -0.01 (-0.06%) 5:24 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, ARS Pharmaceuticals, Inc. has a market cap of $1.75B, which represents its share price of $17.80 multiplied by its outstanding shares number of 98.21M. As a small-cap company, SPRY's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SPRY 17.98 +0.18(1.01%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Other News for SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial ...
ARS Pharmaceuticals Inc (SPRY) Announces Upcoming Conference Call for Q2 2025 Financial Results ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
SPRY Gains Approval for Allergic Reaction Treatment in the UK | SPRY Stock News